Statins in the Era of Evidence-Based Medicine — Who Will Not “Prosper”?

Shepherd J , Cobbe SM , Ford I Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995; 333: 1301–1307.

Sacks FM , Pfeffer MA , Moye LA The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996; 335: 1001–1009.

Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med 1998; 339: 1349–1357.

Downs JR , Clearfield M , Weis S Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998; 279: 1615–1622.

Anonymous. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002 Jul. 6; 360 .(9326.):7.–22. 360: 7–22.

Anonymous. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383–1389.

McFarlane SI , Muniyappa R , Francisco R Pleiotropic effects of statins: lipid reduction and beyond. J Clin Endocrinol Metab. 2002 Apr; 87 (4): 1451–8.

Pasternak RC , Smith SCJ , Bairey-Merz CN , Grundy SM , Cleeman JI , Lenfant C. ACC/AHA/NHLBI Clinical Advisory on the Use and Safety of Statins. Circulation 2002 Aug 20; 106.(8.):1024.-8. 106: 1024–1028.

Haffner SM , Lehto S , Ronnemaa T , Pyorala K , Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction [see comments]. N Engl J Med 1998; 339: 229–234.

Jonsson B , Cook JR , Pedersen TR . The cost-effectiveness of lipid lowering in patients with diabetes: results from the 4S trial. Diabetologia 1999; 42: 1293–1301.

Shepherd J. Economics of lipid lowering in primary prevention: lessons from the West of Scotland Coronary Prevention Study. Am J Cardiol 2001. Mar 8; 87. (5A):19B.-22B.87:19B-22B

Pickin DM , McCabe CJ , Ramsay LE Cost effectiveness of HMG-CoA reductase inhibitor (statin) treatment related to the risk of coronary heart disease and cost of drug treatment. Heart 1999; 82: 325–332.

Hamilton VH , Racicot FE , Zowall H , Coupal L , Grover SA . The cost-effectiveness of HMG-CoA reductase inhibitors to prevent coronary heart disease. Estimating the benefits of increasing HDL-C. JAMA 1995; 273: 1032–1038.

Martens LL , Guibert R. Cost-effectiveness analysis of lipid-modifying therapy in Canada: comparison of HMG-CoA reductase inhibitors in the primary prevention of coronary heart disease. Clin Ther 1994; 16: 1052–1062.

Caro J , Klittich W , McGuire A The West of Scotland coronary prevention study: economic benefit analysis of primary prevention with pravastatin. Br Med J 1997; 315: 1577–1582.

Grover SA , Coupal L , Hu XP . Identifying adults at increased risk of coronary disease. How well do the current cholesterol guidelines work? JAMA 1995; 274: 801–806.

Anonymous. Department of Health. Register of Cost-effectiveness Studies. London:HMSO 1994.

Pickin DM , Payne JN , Haq IU Statin therapy? HMG Co-A reductase inhibitor treatment in the prevention of coronary heart disease. Sheffield: Trent Institute for Health services research, Universities of Leicester, Nottingham and Sheffield, 1996. Guidance Notes for Purchasers: 96/04.

Pyorala K , Wood D. Prevention of coronary heart disease in clinical practice. European recommendations revised and reinforced. Eur Heart J 1998; 19: 1413–1415.

Jones AF . Statins and hypercholesterolaemia: UK Standing Medical Advisory Committee guidelines. Lancet 1997 Oct 18; 350 (9085): 1174–5.

Rabindranath KS , Anderson NR , Gama R , Holland MR . Comparative evaluation of the new Sheffield table and the modified joint British societies coronary risk prediction chart against a laboratory based risk score calculation. Postgrad. Med. J. 2002. May.;78 (919. :269.-72. 78:269–272.

Kannel WB , McGee DL . Diabetes and cardiovascular risk factors: The Framingham Study. Circulation 1979; 1: 8–13.

Ramachandran S , Labib MH . Hyperlipidaemia and primary prevention of coronary heart disease: Are the right patients being treated? J Cardiovasc Risk 2000 Aug.; 7 (4.): 2459. 7: 245–249.

Brady AJ , Oliver MA , Pittard JB . Secondary prevention in 24, 431 patients with coronary heart disease: survey in primary care. Br Med J 2001. Jun. 16; 322. (7300.):1463. 322:1463

Anonymous. Executive Summary of The Third report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001. May 16; 285. (19.):2486–97. 285: 2486–2497.

Scottish Intercollegiate Guidelines Network Publication Number 40. Lipids and the primary prevention of coronary heart disease. Sept 99.

Evans JM , Wang J , Morris AD . Comparison of cardiovascular risk between patients with type 2 diabetes and those who have had a myocardial infarction: cross sectional and cohort studies. Br Med J 2002 Apr 20.; 324 (7343.): 939–42. 324:939–942.

Colhoun HM , Thomason MJ , Mackness MI Design of the Collaborative Atorvastatin Diabetes Study (CARDS) in patients with type 2 diabetes. Diabet Med 2002 Mar; 19 (3): 201–11.

Shepherd J , Blauw GJ , Murphy MB Pravastatin in elderly individuals at risk of vascular disease (PROSPER): randomized controlled trial. Lancet 2002 Nov 23; 360 (9346): 1623–30.

Collins R , Armitage J. High risk elderly patients PROSPER from cholesterol-lowering therapy. Lancet 2002 Nov 23; 360 (9346): 1618–9.

Anonymous. Major outcomes in moderately hypercholesterolaemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). JAMA 2002 Dec 18; 288 (23): 2998–3007.